ALKBH5 loss fosters a more immunostimulatory microenvironment in glioma through an expanded T-cell presence-marked by increased CD4+and CD8+T lymphocyte counts and a higher CD8+/CD4+ ratio-coupled with a reduction in PD-L1 protein expression239. Here, ALKBH5 is linked to central nervous system cancer.